Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus (Nasdaq: AGEN), an immuno-oncology company, has announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York. The company's Chief Commercial Officer, Robin Taylor, Ph.D., will join a panel discussion focused on 'What It Takes to Move the Needle in Improving Responses in Colorectal Cancer.' The event is scheduled for February 28th, 2025, from 1:00-2:00 p.m. ET. This in-person conference requires interested attendees to contact B. Riley for participation details.
Agenus (Nasdaq: AGEN), un'azienda di immuno-oncologia, ha annunciato la sua partecipazione alla Conferenza per Investitori sulla Oncologia di Precisione e Radioterapia di B. Riley Securities a New York. Il Chief Commercial Officer dell'azienda, Robin Taylor, Ph.D., parteciperà a una discussione di panel incentrata su 'Cosa Serve per Migliorare le Risposte nel Cancro Colorettale.' L'evento è programmato per il 28 febbraio 2025, dalle 13:00 alle 14:00 ET. Questa conferenza in presenza richiede ai partecipanti interessati di contattare B. Riley per i dettagli sulla partecipazione.
Agenus (Nasdaq: AGEN), una empresa de inmuno-oncología, ha anunciado su participación en la Conferencia de Inversores sobre Oncología de Precisión y Radioterapia de B. Riley Securities en Nueva York. La Directora Comercial de la empresa, Robin Taylor, Ph.D., se unirá a una discusión en panel centrada en 'Lo que se Necesita para Mejorar las Respuestas en el Cáncer Colorrectal.' El evento está programado para el 28 de febrero de 2025, de 1:00 a 2:00 p.m. ET. Esta conferencia presencial requiere que los asistentes interesados se pongan en contacto con B. Riley para obtener detalles sobre la participación.
Agenus (Nasdaq: AGEN), 면역종양학 회사가 뉴욕에서 열리는 B. Riley Securities 정밀 종양학 및 방사선 치료 투자자 회의에 참여한다고 발표했습니다. 회사의 최고 상업 책임자인 Robin Taylor, Ph.D.가 '대장암 치료 반응 개선을 위한 필수 요소'에 대한 패널 토론에 참여할 예정입니다. 이 행사는 2025년 2월 28일 오후 1시부터 2시까지(ET) 예정되어 있습니다. 이 대면 회의에 참석하고자 하는 관심 있는 분들은 참여 세부 정보를 위해 B. Riley에 연락해야 합니다.
Agenus (Nasdaq: AGEN), une entreprise d'immuno-oncologie, a annoncé sa participation à la Conférence des Investisseurs sur l'Oncologie de Précision et la Radiopharmacie de B. Riley Securities à New York. Le Directeur Commercial de l'entreprise, Robin Taylor, Ph.D., participera à une discussion en panel axée sur 'Ce qu'il faut pour améliorer les réponses dans le cancer colorectal.' L'événement est prévu pour le 28 février 2025, de 13h00 à 14h00 ET. Cette conférence en personne nécessite que les participants intéressés contactent B. Riley pour les détails de participation.
Agenus (Nasdaq: AGEN), ein Unternehmen für Immunonkologie, hat seine Teilnahme an der B. Riley Securities Precision Oncology & Radiopharma Investorenkonferenz in New York bekannt gegeben. Der Chief Commercial Officer des Unternehmens, Robin Taylor, Ph.D., wird an einer Podiumsdiskussion teilnehmen, die sich mit 'Was nötig ist, um die Reaktionen bei kolorektalem Krebs zu verbessern' befasst. Die Veranstaltung ist für den 28. Februar 2025, von 13:00 bis 14:00 Uhr ET, angesetzt. Diese Präsenzkonferenz erfordert, dass interessierte Teilnehmer B. Riley für Details zur Teilnahme kontaktieren.
- None.
- None.
Panel Discussion Details:
Speaker: Robin Taylor, Ph.D., Chief Commercial Officer
Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’
Date: 02/28/2025
Time: 1:00-2:00 p.m. ET
Location:
This event is for in-person participants only. Contact B. Riley for information on attending the conference.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225022116/en/
Investors
917-362-1370
investor@agenusbio.com
Media
510-323-5188
communications@agenusbio.com
Source: Agenus Inc.
FAQ
When is Agenus (AGEN) participating in the B. Riley Securities Oncology Conference 2025?
What topic will Agenus (AGEN) discuss at the B. Riley Securities Conference?
Who will represent Agenus (AGEN) at the B. Riley Securities Investor Conference?
Is the B. Riley Securities Conference featuring Agenus (AGEN) available virtually?
